Conjugates of desferrioxamine with 5-aminolevulinic or γ-aminobutyric acid: synthesis, theoretical studies, iron-chelating ability, and penetration in human Caco-2 cells
Ernani Lacerda, Vasilii D. Khripun, M. Teresa Machini, Breno Pannia Espósito · 2026
Read Conjugates of desferrioxamine with 5-aminolevulinic or γ-aminobutyric acid: synthesis, theoretical studies, iron-chelating ability, and penetration in human Caco-2 cells by Ernani Lacerda, Vasilii D. Khripun, M. Teresa Machini, Breno Pannia Espósito (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13518394.txt.
Description
Ernani Lacerda and three colleagues upgrade a classic iron-removing drug in a 2026 chemistry study. Desferrioxamine grabs iron superbly but slips poorly into cells, limiting it against the iron overload tied to brain diseases. The team welded it to two small amino acids known for crossing barriers: 5-aminolevulinic acid and GABA. Both welded versions were purified and fully characterised by spectrometry and magnetic resonance methods.
Both kept the parent drug's iron grip and antioxidant strength, barely stuck to blood proteins, and could not strip iron from its carrier protein. In human gut-barrier cells both proved harmless, yet only the GABA version reached inside and bound the cell's own iron. Computer modelling matched the bench results closely enough to predict new candidates. Lacerda's team names GABA-DFO a promising intracellular chelator for overload therapy.
Catalog record
| CREATOR | Ernani Lacerda, Vasilii D. Khripun, M. Teresa Machini, Breno Pannia Espósito |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50474 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |